Senti Biosciences (SNTI) investor relations material

Opening remarks and agenda

• Meeting called to order as a continuation of the meeting adjourned on October 8, 2026; stockholders of record on September 23, 2026, were eligible to vote.

• Six proposals covered director elections, auditor ratification, Nasdaq share issuance approval, merger approval, a reverse stock split, and possible adjournment.

Board and executive committee updates

• Timothy Lu, Edward Mathers, and Frances D. Schulz were elected as Class I directors to serve until the 2029 annual meeting, subject to earlier departure or successor qualification.

Shareholder proposals

• Proposal 3 sought approval to issue more than 19.99% of outstanding common shares upon exchange of senior secured convertible notes issued by wholly owned subsidiary Senti Holdings, Inc.

• Proposal 4 sought approval of the July 14, 2026 merger agreement involving Celadon Partners SPV-35 Limited, Senti Merger Sub, Inc., Senti Holdings, Inc., and Senti Biosciences, Inc.

• Proposal 5 sought authority for a 1-for-20 to 1-for-50 reverse split, with the ratio set at the board’s discretion and authority to abandon the amendments.

• Proposal 6 sought approval to adjourn the meeting if votes were insufficient to approve the merger agreement.